Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Haematologica ; 95(5): 724-9, 2010 May.
Article in English | MEDLINE | ID: mdl-20007138

ABSTRACT

BACKGROUND: beta-thalassemia is a rare disease in France, encountered mainly in patients originating from Italy and North Africa. In the setting of the recent French plan for rare diseases, a National Registry for thalassemia has been developed since 2005. Epidemiological and clinical data have been collected on living patients with beta-thalassemia major or intermedia, including those who underwent hematopoietic stem cell transplantation. DESIGN AND METHODS: A standardized questionnaire was sent to clinicians throughout the national professional networks involved in the management of thalassemic patients and data were updated every 18 months. A cross-sectional study was performed in February 2009. RESULTS: Data on 378 patients (267 with thalassemia major) with a median age of 20 were recorded. Hematopoietic stem cell transplantation was performed in 52 patients. Stature, rates of parenthood, splenectomy, and cholecystectomy were no different between non-transplanted thalassemia major and thalassemia intermedia patients, after adjustment for age. Among the 215 non-transplanted thalassemia major patients, the median serum ferritin level was 1240 ng/mL and the rates of iron-related complications were 10%, 6%, 10% and 48% for cardiac failure, diabetes, hypothyroidism, and hypogonadism, respectively. From 2005 to 2008, a dramatic switch in chelation treatment, from deferoxamine to deferasirox, was observed. CONCLUSIONS: The rates of complications of iron overload in French thalassemia major patients appeared similar to those reported in other developed countries in which this condition is not endemic. There were no significant differences in height and parenthood rates between patients with the major and the intermedia forms of the disease, underlining the progress in clinical care. Future developments will focus on mortality and morbidity under oral chelation treatment.


Subject(s)
Registries , beta-Thalassemia/complications , beta-Thalassemia/therapy , Adolescent , Adult , Cardiovascular Diseases/complications , Cardiovascular Diseases/epidemiology , Cardiovascular Diseases/therapy , Child , Child, Preschool , Cohort Studies , Cross-Sectional Studies , Diabetes Complications/complications , Diabetes Complications/epidemiology , Diabetes Complications/therapy , Female , Follow-Up Studies , France/epidemiology , Humans , Infant , Iron Overload/complications , Iron Overload/epidemiology , Iron Overload/therapy , Male , Middle Aged , Treatment Outcome , Young Adult , beta-Thalassemia/epidemiology
2.
Surg Endosc ; 22(1): 45-9, 2008 Jan.
Article in English | MEDLINE | ID: mdl-17943384

ABSTRACT

INTRODUCTION: Partial splenectomy (PS) in children is a surgical option in haematological diseases and focal splenic tumours. The aim of this study was to describe the feasibility and the results of laparoscopic partial splenectomy in children in these two indications by a multicentric retrospective study. METHODS: The authors reviewed the files of all children who underwent laparoscopic PS between March 2002 and September 2006 in two paediatric surgical centers. The data of 11 children were collected and included clinical presentation, age, gender, radiographic examinations, surgical procedure, need for blood transfusion and early complications. RESULTS: From March 2002 to September 2006, laparoscopic PS had been performed on 11 children (6 boys, 5 girls) aged 23 months to 11 years (mean 7, 9). Four children had splenic focal tumours and seven had haematological diseases: six hereditary spherocytosis (HS) and one hemoglobinosis E. During the surgical procedure for haematological diseases 75-80% of the splenic tissue was removed. When PS was performed for focal splenic tumours, the splenic remnant was around 70%. No preoperative complications occurred (no bleeding, no diaphragmatic injury). Neither preoperative nor conversion was necessary. One postoperative complication occurred (left pleural effusion) but required no further treatment. The mean hospital stay was 7.7 days (range from 3 days to 10 days). No infectious postoperative complications occurred; the mean follow up was 21.1 months (range 3-52 months). CONCLUSION: Laparoscopic partial splenectomy is feasible and safe in children with hypersplenism or focal splenic tumours. Partial splenectomy is a good way to prevent postsplenectomy infections by preservation of the immune role of spleen in children with haematological diseases. This technique performed for focal splenic tumours allows the surgeon to choose the size of the splenic remnant.


Subject(s)
Hematologic Neoplasms/complications , Laparoscopy/methods , Splenectomy/methods , Splenic Diseases/surgery , Age Factors , Child , Child, Preschool , Epidermal Cyst/complications , Epidermal Cyst/pathology , Female , Follow-Up Studies , Hemangioma/complications , Hemangioma/pathology , Hematologic Neoplasms/pathology , Humans , Infant , Laparoscopy/adverse effects , Length of Stay , Male , Neoplasm Staging , Pain, Postoperative , Postoperative Complications , Retrospective Studies , Risk Assessment , Spherocytosis, Hereditary/complications , Spherocytosis, Hereditary/pathology , Splenic Diseases/etiology
SELECTION OF CITATIONS
SEARCH DETAIL
...